BioSpace News Archive

A new peer-reviewed study from Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), shows that pharmacist recommendations driven by its unique medication decision support system, MedWise® Science, can help prescribers identify and reduce the levels of potentially inappropriate medications among older adults, reducing the risk of negative cognitive and physical outcomes.

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its HeartBeam AIMI™ platform technology for use in diagnosing heart attacks.

GITAI USA Inc. (GITAI), the world’s leading space robotics company, developed the GITAI IN1 (Inchworm One), a robotic arm equipped with “grapple end-effectors* " on both ends of the arm.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Notice of Allowance has been received from the European Patent Office (EPO) for claims involving compositions of proenzymes to treat cancer.

Cleartronic, Inc. (OTCPINK: CLRI) released its 2022 third quarter financial statements for the nine months ended June 30, 2022.

ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) today announced that ALX Oncology’s next generation CD47 blocker, evorpacept, has been selected for a new investigational treatment arm in the I-SPY-P1 TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer.

MCRA, LLC is pleased to announce the formation and expansion of its biocompatibility division, led by former FDA biocompatibility reviewer Robert A.

Novadoz Pharmaceuticals is pleased to announce the launch of several new products to add to its diverse portfolio of generic medicines.

Bluejay Therapeutics announced today that it has closed a $41 million Series B round of finance led by Arkin Bio Ventures.

AstraZeneca and Merck today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).